title: Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study.
abstract: From January 1984 to December 1986, 94 patients with unresectable, locally advanced, non-small cell lung cancer (NSCLC) were treated to assess both the efficacy and the toxicity of a combined modality treatment including radiation therapy (45 Gy/15 fractions/3 weeks) and daily low dose cDDP (6 mg/m2). The overall response rate for the 90 evaluable patients was 54.3% with 16.6% of complete responses. At a minimum follow-up of 4 years, the overall median survival time was 12 months. Provided adequate hydration is ensured, the cDDP regimen chosen as a radiosensitizer can be safely combined with radiation therapy.
authors.affiliation: Radiotherapy Division, Centro di Riferimento Oncologico, Aviano, Italy.
authors.forename: M G
authors.initials: MG
authors.lastname: Trovò
authors.forename: E
authors.initials: E
authors.lastname: Minatel
authors.forename: G
authors.initials: G
authors.lastname: Franchin
authors.forename: C
authors.initials: C
authors.lastname: Gobitti
authors.forename: M
authors.initials: M
authors.lastname: Roncadin
authors.forename: A
authors.initials: A
authors.lastname: De Paoli
authors.forename: M
authors.initials: M
authors.lastname: Arcicasa
authors.forename: G
authors.initials: G
authors.lastname: Boz
authors.forename: R
authors.initials: R
authors.lastname: Bortolus
mesh_terms: D000328:Adult; D000368:Aged; D001834:Body Water; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011879:Radiotherapy Dosage; D015996:Survival Rate
chemical_list: D002945:Cisplatin